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demonstrated after experimental limb I/R injury7,8 and is
a leading cause of morbidity and death after abdominal
aortic aneurysm (AAA) surgery.2,6 Increased numbers of
circulating activated neutrophils have been reported after
limb I/R injury,9,10 and leukosequestration is a feature of
postreperfusion lung injury.11 The development of sys-
temic inflammation after revascularization procedures rep-
resents a complex cascade of proinflammatory mediator,12
cytokine production2,10 and leukocyte recruitment and
activation.9 Several researchers have reported that AAA
repair is associated with portal and systemic endotox-
emia,1,12-15 and revascularization itself has been associated
with increased gut permeability.16,17 Endotoxin, a
lipopolysaccharide component of the cell wall of gram-
negative bacteria, is a potent stimulus to cytokine genera-
tion, coagulation and complement activation,18 and
leukocyte activation.19,20 It has been implicated in the
pathogenesis of human systemic inflammatory response
840
Hind limb ischemia-reperfusion injury (I/R) has been
shown to initiate a systemic inflammatory response syn-
drome,1,2 leading to multiple organ failure,3,4 which car-
ries a high mortality rate in spite of conventional intensive
care support.3,5,6 Acute pulmonary dysfunction has been
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Objectives: Hind limb ischemia-reperfusion (I/R) injury increases gut permeability, and resultant endotoxemia is asso-
ciated with an amplified systemic inflammatory response syndrome leading to multiple organ dysfunction syndrome.
We studied the potential role of recombinant bactericidal/permeability–increasing protein (rBPI21), a novel antiendo-
toxin therapy, in modulating endotoxin-enhanced systemic inflammatory response syndrome in hind limb I/R injury.
Methods: In this prospective, randomized, controlled, experimental animal study, 48 male Wistar rats, weighing 300 to
350 g, were randomized to a control group (sham) and five groups undergoing 3 hours bilateral hind limb ischemia with
2 hours reperfusion (I/R) (n = 8 per group). The control and untreated I/R groups received thaumatin, a control-
protein preparation, at 2 mg/kg. Treatment groups were administered rBPI21 intravenously at 1, 2, or 4 mg/kg body
weight at the beginning of reperfusion; an additional group was administered rBPI21 intravenously at 2 mg/kg after
1 hour of reperfusion. Plasma interleukin-6 concentration was estimated by bioassay as a measure of systemic inflam-
mation. Plasma endotoxin concentration was determined by use of an amebocyte lysate chromogenic assay. Cross-
reactive immunoglobulin G and M antibodies to the highly conserved inner core region of endotoxin were measured
by use of an enzyme-linked immunosorbent assay. The lung tissue wet-to-dry weight ratio and myeloperoxidase con-
centration were used as markers of edema and neutrophil sequestration, respectively.
Results: I/R provoked highly significant elevation in plasma interleukin-6 concentrations (1351.20 pg/mL [860.16 -
1886.40 pg/mL]) compared with controls (125.32 pg/mL [87.76-157.52 pg/mL; P < .0001]), but treatment with
rBPI21 2 mg/kg at onset of reperfusion (715.89 pg/mL [573.36-847.76 pg/mL]) significantly decreased interleukin-
6 response compared with the nontreatment group (P < .016). I/R increased plasma endotoxin concentrations signif-
icantly (21.52 pg/mL [6.20-48.23 pg/mL]), compared with control animals (0.90 pg/mL [0.00-2.30 pg/mL; P <
.0001]), and treatment with rBPI21 4 mg/kg at reperfusion significantly decreased endotoxemia (1.30 pg/mL [1.20-
2.20 pg/mL]), compared with the untreated group (P < .001). The lung tissue myeloperoxidase level was significantly
increased in the untreated I/R group (208.18% [128.79%-221.81%]), compared with in controls (62.00% [40.45%-
80.92%; P < .0001]), and attenuated in those treated with rBPI21 2 mg/kg (129.54% [90.49%-145.78%; P < .05]).
Data represent median and interquartile range, comparisons made with the nonparametric Mann-Whitney U test.
Conclusions: These findings show that hind limb ischemia-reperfusion injury is associated with endotoxemia, elevations
in plasma interleukin-6, and pulmonary leukosequestration. Treatment with rBPI21 after ischemia reduces endotox-
emia, the interleukin-6 response, and attenuates pulmonary leukosequestration in response to hind limb reperfusion
injury. (J Vasc Surg 2001;33:840-6.)
syndrome16,21 and acute lung injury after lower limb I/R
injury.19,21-24 The gut, with its large resident bacterial
population25 is acknowledged as a major source of
endogenous endotoxin in a range of septic responses to
injury.1,22,26 Recently, at this center it has been shown that
lower limb I/R is associated with altered gut permeability
and changes in villus structure.17 This in turn was associ-
ated with an increased systemic endotoxin concentration
and significantly increased levels of interleukin-6 (IL-
6).27,28 The concentration of IL-6, a pleiotropic cytokine,
is known to correlate with the degree of systemic inflam-
mation, prognostic scores, and death.29,30
Bactericidal/permeability-increasing protein (BPI), an
antibacterial protein isolated from human neutrophils, binds
lipopolysaccharide; competitively inhibits lipopolysaccharide-
induced polymorphonuclear leukocyte stimulation; alters
bacterial cell wall permeability, causing cell death; and
reduces many of the harmful effects of endotoxin both in
vitro and in vivo.31-33 Recent reports on recombinant
amino-terminal fragments and analogues of BPI (rBPI21 and
rBPI23) have demonstrated increased survival rates, reduced
cytokine production, and decreased hemodynamic and
metabolic derangement associated with lethal endotoxin
challenge in animals34 and human beings.35
The purpose of this study was to determine whether
treatment after ischemia with antimicrobial rBPI21 would
inhibit endotoxin-induced systemic inflammation after
hind limb I/R injury. We also proposed to determine
whether neutralizing endotoxin with rBPI21 would also
attenuate acute lung injury associated with I/R injury.
MATERIAL AND METHODS
Animal model
Adult male Wistar rats weighing 300 to 350 g
obtained from a breeding colony were used throughout.
Animals were kept under standard conditions and had free
access to standard rat chow and water. Before the experi-
ment, animals were fasted overnight but were allowed
water as desired. The animals were anesthetized with sub-
cutaneous ketamine 80 mg/kg and xylazine 8 mg/kg and
allowed to breathe spontaneously. Hydration was main-
tained by injection of sterile 0.9% sodium chloride, 3
mL/kg per hour subcutaneously. With a heat lamp, body
temperature was kept at 37°C. Bilateral hind limb
ischemia was induced by application of rubber band
tourniquets high around each thigh, a highly reproducible
technique previously reported by our group.17 At the end
of the ischemic period, reperfusion of the limbs was
achieved by releasing the tourniquets. All procedures
involving animals were carried out in accordance with the
regulations of the United Kingdom Animals (Scientific
Procedures) Act, 1986.
Treatment
All rats were randomized before the induction of anes-
thesia to receive treatment with either rBPI21, at various
doses, or the control protein thaumatin (XOMA [US]
LLC, Berkeley, Calif). The controls underwent 5 hours of
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anesthesia, and all I/R injury groups underwent 3 hours
of bilateral hind limb ischemia followed by 2 hours reper-
fusion on release of tourniquets. The rBPI21 was adminis-
tered to three (I/R) groups (n = 8 per group)
intravenously at 1, 2, or 4 mg/kg at the beginning of
reperfusion. An additional (I/R) group (n = 8) was
administered rBPI21 intravenously at 2 mg/kg after 1
hour of reperfusion. The control group and the untreated
I/R group (n = 8 per group) received thaumatin as a 
control-protein preparation at 2 mg/kg.
Blood and tissue sampling. Blood and tissue sam-
ples were obtained after 2 hours of reperfusion. The chest
wall was cleansed with chlorhexidine in spirit, a 1-cm disc
of skin was excised, and a butterfly needle connected to a
10-mL syringe was then used to obtain a blood sample by
direct heart puncture. Blood samples were collected in
heparinized (20 U/mL blood) sterile pyrogen-free tubes,
and immediately transferred on ice to be spun in a cen-
trifuge at 200 rpm (at 4°C) for 10 minutes. Plasma was
aliquoted into sterile cryotubes (Nunc; Intermed,
Roskidle, Denmark) and stored at –70°C until the time of
assay. Immediately after blood sampling, a midline thora-
cotomy was performed, and the entire right lung was
excised, placed immediately in a sterile pyrogen-free cry-
otube (Nunc), snap-frozen in liquid nitrogen, and stored
at –70°C until time of assay.
IL-6 assay. Biologically active IL-6 was measured by
use of a bioassay on the basis of the proliferation of IL-
6–dependent B9 hybridoma cells (a generous gift of L.
Aarden, Amsterdam, The Netherlands). Samples were
serially diluted with IL-6–free growth medium and dis-
pensed in duplicate into 96-well microtiter plates.
Similarly a standard curve ranging from 0 to 500 pg/mL
was generated by use of recombinant human IL-6 (British
Biotechnology, Cowley, United Kingdom) and plated out
in duplicate. B9 cells were washed free of IL-6 and resus-
pended in IL-6–free B9 growth medium. Standard cell
suspension (2.5 × 104/mL) 100 µL was plated into wells
and incubated at 37°C for 4 days. MTT (3-[4,5-
dimethylthiazol-2yl]-2,5 diphenyltetrazolium bromide) in
phosphate-buffered saline solution (0.5 mg/mL) was
added to each well, followed 5 hours later by sodium
dodecyl sulfate 50 mL (20% in 0.01 mol/L hydrochloric
acid). The plates were incubated for another 24 hours.
Absorbance was then read at 570 nm, and the amount of
IL-6 in each sample was computed from the standard
curve. Interassay and intraassay coefficients of variation
were less than 10%.
Antiendotoxin antibody assay. The “EndoCAb”
enzyme-linked immunosorbent assay, which measures
antibody levels to the core glycolipid region of
lipopolysaccharide, was used to measure antiendotoxin
antibody levels. The microplates (G. R. Barclay, Scottish
Blood Transfusion Centre, Edinburgh, United Kingdom)
were previously coated with a “cocktail” of core
lipopolysaccharide from rough mutants of a number of
bacteria in a complex with polymyxin and then blocked
with 5% bovine serum albumin. Plasma samples were
diluted 1:200 by use of phosphate buffered saline solu-
tion, pH 7.4, containing 0.05% Tween (Sigma, Poole,
United Kingdom), 0.5% bovine serum albumin (Sigma),
and 4% polyethylene glycol (BDH Chemicals, Poole,
United Kingdom). A normal plasma dilution curve was
obtained by use of plasma at a range of dilution from 1:50
to 1:1600. Standards and samples were added to the plate
at 100 µL per well. The plate was incubated for 1 hour at
room temperature with continuous shaking. A 1:250 dilu-
tion of the antirat immunoglobulin G (IgG) peroxidase or
1:500 dilution of the antirat immunoglobulin M (IgM)
peroxidase (Serotec, Oxford, United Kingdom), prepared
in the above diluent, was then added to each well (100 
µL) for 1 hour at room temperature with continuous
shaking. After this, 100 µL 3,3,5,5,tetramethyl-benzidine
substrate (Sigma) was added to each well for 10 minutes,
and the reaction was stopped with sulphuric acid 2 mol/L.
The plate was then read on a Thermomax kinetic reader
(Molecular Devices, Crawley, United Kingdom) at an
absorbance of 450 nm, and the results were calculated as
a percentage of the normal range.
Endotoxin. Endotoxin concentration was determined
by use of a quantitative Limulus amebocyte lysate chro-
mogenic assay (Quadratech, Epsom, United Kingdom). The
detection limits of the assay were between 0.1 to 100
pg/mL, interassay coefficient of variation was less than 10%,
and intra-assay coefficient of variation was less than 10%.
Measurement of lung tissue myeloperoxidase. The
specimen (200-400 mg) was minced in a beaker containing
1 mL of hexadecyltrimethylammonium bromide buffer on
ice, transferred to a test tube, and homogenized with a
Polytron homogenizer (Phillip Harris International, Ashby
de la Zouch, Leicestershire, United Kingdom) (3 times for
30 seconds each, on ice) to determine myeloperoxidase
activity in tissue. After homogenization the homogenizer
was rinsed twice with 1 mL of HTAB. The pooled
homogenate and washes were sonicated for 10 seconds,
freeze-thawed thrice, and spun in a centrifuge at 40,000 g
for 15 minutes. The supernatant was assayed for myeloper-
oxidase activity. Myeloperoxidase activity was measured
spectrophotometrically: 0.1 mL of supernatant was com-
bined with 2.9 mL of 50 mmol/L phosphate buffer, pH
6.0, containing 0.167 mg/mL O-dianisidine hydrochloride
and 0.0005% hydrogen peroxide. The change in
absorbance at 460 nm was measured with a Beckmann DU-
2 spectrophotometer (Beckmann Instruments, Inc, Cedar
Grove, NJ). One unit of myeloperoxidase activity is defined
as that degrading 1 µmol of peroxide per minute at 25°C.
Lung tissue wet-to-dry weight ratios. Wet-to-dry
ratios of lung tissue samples (200-400 mg) were calcu-
lated. Each specimen was blotted dry, weighed, and then
placed in a vacuum freeze dryer at –70°C for 48 hours.
Specimens were then reweighed, and the wet-to-dry tissue
weight ratio was calculated.
Statistical analysis
Results are expressed as the median (interquartile
range). A nonparametric one-way analysis of variance
(Kruskal-Wallis H) was used to detect differences between
groups, and statistical comparisons were made by use of
the Mann-Whitney U test. A P value of .05 or less was
considered to indicate statistical significance. Analysis was
performed with the software package SPSS version 9.0 for
Windows (SPSS Inc, Chicago, Ill).
RESULTS
Plasma IL-6. Limb I/R increased plasma IL-6 con-
centrations significantly (1352.20 pg/mL [860.16-
1886.40 pg/mL]) compared with control animals
(125.32 pg/mL [87.76-157.52 pg/mL]; P < .0001).
Treatment with rBPI21 intravenously reduced the IL-6
response to bilateral hind limb I/R significantly in all
groups (P < .05); this significance was greatest when
rBPI21 2 mg/kg was given at reperfusion (715.89 pg/mL
[573.36-847.76 pg/mL]) compared with the untreated
group (1352.20 pg/mL [860.16-1886.40 pg/mL]; P <
.016) (Fig 1).
Systemic endotoxemia. Limb I/R increased plasma
endotoxin concentrations significantly (21.52 pg/mL
[6.20-48.23 pg/mL]) compared with control animals
(0.90 [0.00-2.30 pg/mL]; P < .0001). Treatment with
rBPI21 intravenously reduced the endotoxin response to
bilateral hind limb I/R significantly when rBPI21 4
mg/kg was given at reperfusion (1.30 pg/mL [1.20-2.20
pg/mL]) compared with the untreated group (P < .001)
(Table).
A significant decrease in plasma concentrations (per-
cent of control value) of cross-reactive IgG antibodies to
core glycolipid (endotoxin) was observed after 3 hours of
bilateral hind limb ischemia followed by 2 hours of reper-
fusion in the untreated group (37.85% [18.90%-55.53%];
P < .002). No significant consumption compared with
controls was noted in the I/R groups treated with rBPI21
at reperfusion with 2 mg/kg (47.30% [16.85%-288.88%])
and 4 mg/kg (44.70% [28.73%-126.25%]) and at 1 hour
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Fig 1. Effect of bilateral lower I/R injury on plasma IL-6 concen-
tration with comparison to control group and groups treated with
rBPI21. Data represent median (interquartile range). *P < .0001
versus control group, †P < .002 versus control group, ‡P < .05 
versus I/R injury group. IRI, I/R injury.
into reperfusion at 2 mg/kg (63.30% [23.30%-158.70%]).
There was a significant decrease in plasma concentrations
of cross-reactive IgM antibodies to core glycolipid (endo-
toxin) in the I/R group compared with control (P <
.005). There was no significant change in plasma concen-
trations of antiendotoxin antibody IgM in any rBPI21
treated group compared with control (Table).
Lung tissue myeloperoxidase concentration. Limb
I/R significantly increased lung tissue myeloperoxidase
concentration (208.18 [128.79-221.81]) absorbance
units per gram dry tissue, compared with the control
group (62.00 [40.45-80.92]; P < .0001). Treatment with
2 mg/kg rBPI21 at reperfusion significantly decreased
lung tissue myeloperoxidase concentration (129.54
[90.49-145.78]) compared with the untreated group
(208.18 [128.79-221.81]; P < .050) (Fig 2).
Lung wet-to-dry tissue weight. Limb I/R increased
lung tissue wet-to-dry weight ratio (6.08 [5.15-7.89])
compared with the control group, (4.63 [3.59-5.17]; P <
.007. Treatment with 2 mg/kg rBPI21 at reperfusion sig-
nificantly decreased the lung tissue wet-to-dry tissue
weight (4.94 [3.65-5.26]) compared with untreated I/R
injury (6.08 [5.15-7.89]; P < .04); however, this was still
significantly higher than in the control group (4.63 [3.59-
5.17]; P < .02) (Fig 3).
DISCUSSION
Elective or emergency vascular surgical reperfusion of
ischemic lower limbs may be successful technically but still
carries a high morbidity and mortality rate in an increas-
ingly elderly patient population.3-5 Although optimal sur-
gical technique and critical care has improved outcomes
after operations for AAA, the rupture mortality rate is still
30% to 70%.3,36 At least 20% of these deaths are attribut-
able to multiple organ failure,3,6 the leading cause of death
in surgical intensive care units.37 Our own group17 and
others16,38 have shown that lower limb I/R is associated
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with remote gut mucosal injury and increased permeabil-
ity. We have previously reported that increased levels of
endotoxin, a lipopolysaccharide component of gram-neg-
ative bacterial cell wall, is associated with elevations in sys-
temic IL-6 concentrations and high mortality rates in an
experimental model of hind limb I/R injury.27 Increased
endotoxin levels have also been reported in human beings
after AAA repair.21 More recently, endotoxemia has been
shown to predict death after thoracoabdominal aortic
aneurysm repair.19 In our study the modulation of the IL-
6 response and remote acute lung injury by rBPI21, an
antibacterial and antiendotoxin agent, suggests that gut-
derived endotoxin may well amplify the septic response to
lower limb I/R injury.
Previous work on this model of bilateral hind limb
I/R at this center has demonstrated remote gut injury,
systemic endotoxemia, and elevated systemic IL-6.27,28
Endotoxins are responsible for metabolic derangement,
vascular endothelial damage, and cardiovascular changes
resulting in hypotension and shock.18,39,40 These also
stimulate cytokine production, including significant
release of IL-6.41 Svoboda et al29 and Calandra et al42
have shown a close correlation between IL-6 levels and
injury severity score and survival after trauma and sepsis,
respectively. In this study rBPI21 has been used to signifi-
cantly diminish the IL-6 response to lower limb I/R. We
have previously reported elevations in tumor necrosis fac-
tor–alpha early in the reperfusion period in a survival
model of rat I/R injury.27 Tumor necrosis factor, an early
proinflammatory mediator, partially controls the release of
IL-643 and has been implicated in the development of
acute lung injury.44 We measured IL-6 in this study
because it indicates global inflammation and correlates
with outcome.1,42,45 IL-6 has also been associated with
the activation of circulating neutrophils,46 delaying apop-
tosis,47 and therefore prolonging functional longevity and
potential tissue injury. Endotoxin, a potent stimulant of
Fig 2. Effect of bilateral lower I/R injury on lung tissue
myeloperoxidase concentration with comparison to control group
and groups treated with rBPI21. Data represent median
(interquartile range). *P < .0001 versus control group, †P < .002
versus control group, ‡P < .05 versus I/R injury group. IRI, I/R
injury.
Fig 3. Effect of bilateral lower I/R injury on lung tissue wet-to-
dry weight ratio with comparison to control group and groups
treated with rBPI21. Data represent median (interquartile range).
*P < .007 versus control group, †P < .05 versus control group, 
‡P < .04 versus I/R injury group. IRI, I/R injury.
which in turn may help prevent further increased gut per-
meability and consequent endotoxin translocation. In our
present study we witnessed significant consumption of
cross-reactive IgG and IgM antibodies to core glycolipid
(endotoxin) in the untreated I/R group, an outcome
averted in the groups treated with rBPI21. The latter may
represent a reduction in circulating endotoxin binding
with rBPI21 or more rapid phagocytosis of endotoxin
bound to rBPI21.
Sepsis syndrome caused by bacteremia or endotoxemia
remains a leading cause of morbidity and death, in spite of
antibiotics and intensive care support.37 The experimental
finding that antiendotoxin immunotherapy with polyclonal
or monoclonal antibodies reduced mortality rates in a
research setting gave rise to initial optimism.49,50 However
the clinical efficacy and endotoxin binding properties of
these antibodies are now in doubt.50,51 BPI, an antibacte-
rial protein isolated from human neutrophils,32,33 has been
found to bind endotoxin and inhibit endotoxin-mediated
neutrophil and monocyte activation. BPI (and its N-termi-
nal fragments and analogues) has certain advantages over
these antibodies, namely, that it is neither serotype specific
nor inhibited by the O-specific side chain of lipopolysac-
charide.31,33,52 It therefore is not rendered ineffective in
overwhelming infection by heterogenous organisms. Our
control protein thaumatin, an intensely sweet protein iso-
lated from the African plant Thaumacoccus danielli, has a
molecular weight and an isoelectric point similar to that of
rBPI21 but does not bind to lipopolysaccharide or affect its
ability to induce cytokine release in vitro.53 The short
plasma half-life of rBPI21,54 means that the timing of drug
delivery to limit endotoxin-induced inflammatory activa-
tion may be crucial. In further studies a continuous intra-
venous infusion during early reperfusion may overcome
rapid rBPI21 plasma clearance. There is a growing body of
evidence supporting a role for gut hyperpermeability13,16
and translocation of endotoxin15 in the propagation of the
inflammatory response to AAA surgery.1,21 If gut endo-
toxin converts a recoverable inflammatory response to a
lethal endotoxemia in a certain subset of patients, then
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IL-6 release,41 is neutralized by rBPI21, but the drug also
directly inhibits polymorphonuclear stimulation by endo-
toxin.32,33 The reduced IL-6 response may also be repre-
sentative of a general decrease in inflammation and
cytokine production.
Reperfusion of postischemic tissue initiates a systemic
inflammatory response syndrome characterized by pro-
duction of proinflammatory mediator production, neu-
trophil and monocyte activation, and hemodynamic and
metabolic derangement.2,9,30 I/R of lower limb is also
associated with an acute lung injury or adult respiratory
distress syndrome,48 characterized by increased microvas-
cular permeability and polymorphonuclear infiltration.7,9
We have demonstrated in this model that I/R is associated
with acute pulmonary edema and polymorphonuclear
leukocyte infiltration and that it can be partially attenuated
by use of rBPI21. Endotoxin is a potent stimulus to neu-
trophil activation. Therefore the beneficial effects of
rBPI21 may be due to its role in promoting direct clear-
ance of endotoxin and indirect attenuation of phagocytic
cell activation in response to endotoxin. It may also be a
reflection of a generalized diminished systemic inflamma-
tory response syndrome in these animals in which we have
shown a highly significant decrease in plasma IL-6. The
lungs in the untreated I/R group showed a dense poly-
morphonuclear infiltrate on histologic assessment.
Previous work at this center has shown that isolated
hind limb I/R leads to systemic endotoxemia.28 This was
associated with consumption of endogenous antibodies
(IgG and IgM) directed against inner core glycolipid of
endotoxin (EndoCAb). These findings are in agreement
with those of other workers37 who have correlated low
EndoCAb levels with high endotoxin concentrations in
patients with sepsis. We have again demonstrated endo-
toxemia after hind limb I/R. The prevention of detectable
systemic endotoxemia in the rBPI21-treated groups may
reflect increased clearance of endotoxin; rBPI21 has been
shown to increase phagocytic cell clearance of endotoxin
in vitro and in vivo.17,31,34 There is also decreased sys-
temic inflammation (IL-6) in the rBPI21-treated group,
Systemic endotoxemia
Indexes of systemic endotoxemia
Group (n = 8) Endotoxin (pg/mL) EndoCAb IgG (% control) EndoCAb IgM (% control)
Control 0.9 (0.0-2.3) — —
I/R 21.5 (6.2-48.2)* 37.9 (18.9-55.5)† 62.3 (53.3-70.8)†
I/R + rBPI21 (1 mg/kg) 2.5 (2.0-3.20)‡ 24.9 (14.7-35.3)† 89.5 (72.6-131.6)
I/R + rBPI21 (2 mg/kg) 2.5 (2.0-5.4)‡ 47.3 (16.9-288.9) 82.7 (62.9-230.7)
I/R + rBPI21 (4 mg/kg) 1.3 (1.2-2.2)§ 44.7 (28.7-126.3) 106.5 (51.4-127.1)
I/R + rBPI21 (2 mg/kg) at 3.5 (2.7-4.0)‡ 63.3 (23.3-158.7) 135.0 (83-150.7)
1 h into reperfusion
The effect of bilateral lower I/R injury on plasma EndoCAb IgG concentration with comparison to control group and groups treated with rBPI21. Results
expressed as percentage of pooled control plasma (control = 100%). Data represent median (interquartile range).
*P < .0001 versus control group.
†P < .005 versus control group.
‡P < .05 versus I/R injury group.
§P < .001 versus I/R injury group.
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rBPI21 may represent an important advance in the treat-
ment of these patients.
In conclusion, this study clearly shows that rBPI21 can
significantly reduce the IL-6 response to lower limb I/R
and attenuation of the neutrophil-mediated acute lung
injury. Although further studies on the mechanism of
action, optimal dose, and time of delivery are required,
these results suggest that rBPI21 may well represent a use-
ful adjuvant therapeutic tool in preventing or attenuating
the septic response to ischemia-reperfusion injury.
We are indebted to Xoma Corporation (US) LLC,
Berkeley, Calif, for generous provision of rBPI21.
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